Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
Based on the PubMed abstract, this review explains how sample selection, experimental balance, outlier handling, transformation, and statistical methods affect anti-drug antibody assay cut points. It addresses screening, confirmation, titers, drug tolerance, and reassessment using clinical baseline samples. This is a practical review of validation decisions, not a new clinical efficacy study.
Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.
Based on the PubMed abstract, a Bioanalysis review examines switchable-hydrophilicity solvents and bio-derived deep eutectic solvents for sample preparation. It discusses extraction performance, matrix effects, reproducibility, and environmental trade-offs, with future emphasis on miniaturization and automation. The review evaluates methodological opportunities rather than validating a specific assay for regulated clinical sample analysis.
The DeepDelivery platform screened the human proteome for proteins that could serve as mRNA delivery scaffolds. Twelve of 15 experimentally tested candidates supported particle formation and delivery within a modular system. Engineering TRIM25 domains improved performance. The work establishes a discovery framework in cultured cells, rather than clinical evidence of reduced immunogenicity.
Labcorp posted a CBF 2026 conference-poster summary describing a direct assay format for neutralizing anti-drug antibodies. The approach is intended to address limitations of competitive assays when drug–target affinity is weak or signals are unstable. The public summary presents the assay concept, rather than quantitative validation results or a peer-reviewed clinical study.
Labcorp's CBF 2026 poster summary describes a unified serum free-IgE assay supporting comparison of two IgE-targeting drug candidates, including a marketed comparator. The team evaluated assay conditions that can disturb drug–IgE equilibrium and reports establishing a fit-for-purpose method. The public summary does not identify the therapies or provide numerical validation metrics; it is a conference report.
The NYSBC, SEMC, and NCCAT course is scheduled for November 2–4, 2026, in New York. Its November 4 agenda includes automation and machine learning, microscope setup, acquisition, and direct-detector practicals, with optional practice on November 5.
Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.
Lipid-polymer hybrid particles combined polymer stability with lipid-mediated transfection. Hyaluronic acid and polyvinyl alcohol coatings helped preserve particle properties after nebulization, while mucus-covered airway cultures retained measurable transfection. Primary human lung fibroblasts and intratracheally dosed mice provided additional delivery evidence. These results support aerosol formulation development, although intratracheal dosing does not establish the performance of inhaled aerosols in patients.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
PharmaBlock Sciences reported consolidated revenue of RMB1.634 billion, up 15.16%, and attributable net income of RMB151.2 million for the nine months ended September 30, 2026. Attributable net income rose 33.36%, while net cash from operations declined 53.75% over the same period. The quarterly filing is unaudited and covers the year-to-date period.
Haoyuan Chemexpress reported consolidated revenue of RMB2.646 billion, up 28.52%, and attributable net income of RMB308.8 million for the nine months ended September 30, 2026. Attributable net income rose 30.49%. Consolidated revenue combines multiple businesses rather than isolating CDMO service revenue. The quarterly filing is unaudited and covers the year-to-date period.
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
